Cortexyme, Inc. (CRTX) News

Cortexyme, Inc. (CRTX): $1.95

0.05 (+2.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter CRTX News Items

CRTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CRTX News Highlights

  • CRTX's 30 day story count now stands at 16.
  • Over the past 23 days, the trend for CRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
  • LAW, MSCI and DRUG are the most mentioned tickers in articles about CRTX.

Latest CRTX News From Around the Web

Below are the latest news stories about Cortexyme Inc that investors may wish to consider to help them evaluate CRTX as an investment opportunity.

Short Sellers Were Right About These 10 Stocks

In this article, we discuss the 10 stocks that short sellers were right about. If you want to skip our detailed analysis of these stocks, go directly to Short Sellers Were Right About These 5 Stocks. Short-sellers were the headliners of early 2021. A year later, these short-sellers are once again in the spotlight amid […]

Yahoo | February 24, 2022

Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks

Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | February 18, 2022

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

NewMediaWire | February 16, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $CRTX #CRTX--The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

Business Wire | February 14, 2022

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation CRTX

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cortexyme securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Business Wire | February 14, 2022

Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Cortexyme, Inc. (NASDAQ: CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/crtx .

GlobeNewswire | February 14, 2022

Alzheimer's drug company to cut workforce in half, pay off exiting execs

Lump-sum cash severance payments to President, CEO and board chair Casey Lynch and Chief Scientific Officer Steve Dominy — two founders of the company — will total nearly $1 million.

Yahoo | February 3, 2022

After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)

The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | February 2, 2022

Cortexyme outlines milestones for 2022

Cortexyme (NASDAQ:CRTX) provided a business update and announced key milestones for 2022. COR588 in mild to moderate Alzheimer’s Disease (AD): COR588 is currently completing a Phase 1 SAD/MAD trial in a cohort of healthy participants in Australia with study results expected in Q2 2022. Following the Phase 1 study, and...

Seeking Alpha | February 1, 2022

5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI

Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today.

William White on InvestorPlace | February 1, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.511 seconds.